Differential Effects of Protein Kinase C Inhibitors on Nuclear and Cytoplasmic DMPK Transcript Dynamics in Myotonic Dystrophy Type 1 Cells
DOI:
https://doi.org/10.83080/rejost.vol6no7.322Abstract
The major molecular basis for myotonic dystrophy type 1 disorder is the occurrence of a mutation leading to expanded CTG triplet units in the 3’-untranslated region of Dystrophia Myotonica Protein Kinase (DMPK) gene, which leads to the formation of foci in the nuclei of these cells. An assay based on the DMPK transcript (Bpm I polymorphism) was developed to test the effect of compounds of protein Kinase C inhibitors- hypericin and Ro 31-8220- to determine whether either inhibitor affected the transport of DMPK transcripts from nucleus to the cytoplasm or reduced the proportion of the transcript in both fibroblast and myoblast cells. The results from this study showed that the protein kinase C inhibitors were not able to affect the relocation of mutant DMPK transcripts from the nucleus to the cytoplasm in both DM1 fibroblasts and myoblasts, but Ro 31-8220 significantly reduced mutant transcripts in the nuclear fraction of DM1 fibroblasts. In the nuclei of fibroblasts, Ro 31-8220 treatment showed a 38.5±5.4% proportion of mutant transcript, hypericin treatment exhibited 54.2±3.5% mutant transcript, while those of DMSO treatment and untreated were 43.7±3.0% and 51.4±0.8%, respectively. For cytoplasmic fractions of DM1 fibroblasts, Ro 31-8220-treated cells indicated 94.4±1.7% normal transcript, hypericin treatment showed 91.6±1.0%, with DMSO-treated and untreated cells having 90.0±1.9% ad 89.5±2.3%, respectively. In the DM1 myoblasts nuclear fraction, 61.8±1.7% mutant transcript was observed in Ro 31-8820- treated cells, 67.5±2.8% mutant transcript occurred in hypericin treatment, while DMSO treatment and untreated cells had 52.4±1.7% and 48.7±0.8%, respectively. In myoblast cytoplasmic fractions, hypericin and Ro 31-8220 showed 90.6±2.7% and 80.8±0.3% normal transcripts, respectively, with DMSO treatment showing 81.1±0.5% normal transcript, while the untreated showed 80.0±5.7% normal transcript. This study has discovered the role of Ro 31-8220 in reducing the proportion of mutant transcripts I nuclear fraction while increasing the levels of the normal transcripts was increased in the cytoplasmic fraction of DM1 cells. Taken together, results from this study suggest that Ro 31-8220 may have therapeutic potential for reducing mutant DMPK transcript levels with potential therapeutic value
References
Brook, J. D., McCurrach, M. E., Harley, H. G., Buckler, A. J., Church, D., Aburatani, H., ... & Housman, D. E. (1992). Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell, 68(4), 799-808.
Davis, B. M., McCurrach, M. E., Taneja, K. L., Singer, R. H., & Housman, D. E. (1997). Expansion of a CUG trinucleotide repeat in the 3′ untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proceedings of the National Academy of Sciences, 94(14), 7388-7393.
Fardaei, M., Larkin, K., Brook, J. D., & Hamshere, M. G. (2001). In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts. Nucleic acids research, 29(13), 2766-2771.
Fardaei, M., Rogers, M. T., Thorpe, H. M., Larkin, K., Hamshere, M. G., Harper, P. S., & Brook, J. D. (2002). Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Human molecular genetics, 11(7), 805-814.
Fu, Y., Pizzuti, A., Fenwick Jr, R., King, J., Rajnarayan, S., Dunne, P. W., ... & Caskey, C. T. (1992). An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science, 255(5049), 1256-1258.
Hamshere, M. G., Newman, E. E., Alwazzan, M., Athwal, B. S., & Brook, J. D. (1997). Transcriptional abnormality in myotonic dystrophy affects DMPK but not neighboring genes. Proceedings of the National Academy of Sciences, 94(14), 7394-7399.
Holt, I., Jacquemin, V., Fardaei, M., Sewry, C. A., Butler-Browne, G. S., Furling, D., ... & Morris, G. E. (2009). Muscleblind-like proteins: similarities and differences in normal and myotonic dystrophy muscle. The American journal of pathology, 174(1), 216-227.
Ketley, A., Chen, C. Z., Li, X., Arya, S., Robinson, T. E., Granados-Riveron, J., ... & Brook, J. D. (2014). High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines. Human molecular genetics, 23(6), 1551-1562.
Kimura, T., Nakamori, M., Lueck, J. D., Pouliquin, P., Aoike, F., Fujimura, H., ... & Sakoda, S. (2005). Altered mRNA splicing of the skeletal muscle ryanodine receptor and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase in myotonic dystrophy type 1. Human molecular genetics, 14(15), 2189-2200.
Lin, X., Miller, J. W., Mankodi, A., Kanadia, R. N., Yuan, Y., Moxley, R. T., ... & Thornton, C. A. (2006). Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Human molecular genetics, 15(13), 2087-2097.
Liquori, C. L., Ricker, K., Moseley, M. L., Jacobsen, J. F., Kress, W., Naylor, S. L., ... & Ranum, L. P. (2001). Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science, 293(5531), 864-867.
Mahadevan, M., Tsilfidis, C., Sabourin, L., Shutler, G., Amemiya, C., Jansen, G., ... & Korneluk, R. G. (1992). Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science, 255(5049), 1253-1255.
Mankodi, A., Urbinati, C. R., Yuan, Q. P., Moxley, R. T., Sansone, V., Krym, M., ... & Thornton, C. A. (2001). Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Human molecular genetics, 10(19), 2165-2170.
Mankodi, A., Takahashi, M. P., Jiang, H., Beck, C. L., Bowers, W. J., Moxley, R. T., ... & Thornton, C. A. (2002). Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Molecular cell, 10(1), 35-44.
Philips, A. V., Timchenko, L. T., & Cooper, T. A. (1998). Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science, 280(5364), 737-741.
Ranum, L. P., & Cooper, T. A. (2006). RNA-mediated neuromuscular disorders. Annu. Rev. Neurosci., 29(1), 259-277.
Savkur, R. S., Philips, A. V., & Cooper, T. A. (2001). Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nature genetics, 29(1), 40-47.
Taneja, K. L., McCurrach, M., Schalling, M., Housman, D., & Singer, R. H. (1995). Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. The Journal of cell biology, 128(6), 995-1002.
Udosen, I. U., & Nya, E. J. (2017). Association of MBL2 codon 34 variant of Exon 1 with severity of tuberculosis in Paediatric Population of South Africa. Advances in Life Science and Technology, 58, 1-9.
Udosen, I. U. (2019). Non-Association of Toll-Like Receptor 2 rs3804099 Polymorphism with Paediatric Tuberculosis in South Africa. Advances in Life Science and Technology, 74, 46-50.
Udosen, I. U. (2020). Protein Kinase C Inhibitor Molecule Effect Partial Reversal of Spliceopathy in Myotonic Dystrophy Type 2 Cell Line. Journal of Natural Sciences Research, 11: 17-22.
Udosen, I. U., Granados, J. T., & Brook, J. D. (2023). A Cell-Based Double Reporter Gene Splicing Assay for Therapeutic Screening in Myotonic Dystrophy. The EuroBiotech Journal, 7(3), 155-164.
Udosen, I., Akpanabiatu, M. I., & Sandy, I. Y. (2026). Reducing muscleblind protein levels causes decreased DMPK transcripts and a muscle-specific chloride channel in myotonic dystrophy type one cell line. Genetics & Applications, 10(1).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Inyang Udofia Udosen, Imo Yellow Sandy, Usenobong Friday Ufot
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Unless a different licence is clearly indicated for a particular article, articles published in the journal are made available under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. This licence permits others to read, download, copy, distribute, share, adapt, and build upon the published work, including for commercial purposes, provided that appropriate credit is given to the original author(s), the article is properly cited, and any changes made to the original work are clearly indicated.
